Clinical utility of cytokeratins as tumor markers

Clinical Biochemistry

Volumn 37, Issue 7, 2004, Pages 529-540

  Barak, Vivian ^a   Goike, Helena ^b   Panaretakis, Katja W ^b   Einarsson, Roland ^c  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b IDL Biotech AB   (Sweden)

^c Fujirebio Diagnostics Inc   (Sweden)

Author keywords

Cancer; CYFRA 21 1; Cytokeratins; Monitoring; Prognosis; TPA; TPS

Indexed keywords

BCG VACCINE; CYTOKERATIN; CYTOKERATIN 18; CYTOKERATIN 19; CYTOKERATIN 19 FRAGMENT; CYTOKERATIN 8; FLUOROURACIL; FOLINIC ACID; PACLITAXEL; PROTEIN ANTIBODY; TISSUE POLYPEPTIDE ANTIGEN; TUMOR MARKER;

ACCURACY; APOPTOSIS; BLADDER CANCER; BODY FLUID; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CELL ACTIVITY; COLORECTAL CANCER; ENZYME DEGRADATION; EPITHELIUM CELL; HEAD AND NECK CANCER; HUMAN; INFORMATION; LUNG CANCER; MEASUREMENT; METASTASIS; MONITORING; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN MOTIF; RECURRENT DISEASE; REVIEW; TUMOR GROWTH;

ANTIGENS, NEOPLASM; FEMALE; HUMANS; KERATINS; MALE; NEOPLASM METASTASIS; NEOPLASMS; PEPTIDES; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TISSUE POLYPEPTIDE ANTIGEN; TUMOR MARKERS, BIOLOGICAL;

EID: 3042598857     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2004.05.009     Document Type: Review

References (103)

1. Parry D., Steinert P.M. Intermediate filaments: molecular architecture, assembly, dynamics and polymorphism. Q. Rev. Biophys. 32:1999;99-187
2. Kirfel J., Magin T.M., Reichelt J. Keratins: a structural scaffold with emerging functions. Cell. Mol. Life Sci. 60:2003;56-71
3. Strelkov S.V., Herrman H., Aebi U. Molecular architecture of intermediate filaments. BioEssays. 25:2003;243-251
4. Osborn M., Weber K. Intermediate filaments: cell-type specific markers in the differentiation and pathology. Cell. 31:1982;303-306
5. Fuchs E., Weber K. Intermediate filaments: structure, dynamics, function and disease. Ann. Rev. Biochem. 63:1994;345-382
6. Moll R., Franke W.W., Schiller D.L., Geiger B., Krepler R. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell. 31:1982;11-24
7. Hatzfeld M., Franke W.W. Pair formation and promiscuity of cytokeratins: formation in vitro of heterotypic complexes and intermediate-sized filaments by homologous and heterologous recombinations of purified polypeptides. J. Cell Biol. 101:1985;1826-1841
8. Coulombe P.A., Omary M.B. "Hard" and "soft" principles defining the structure, function and regulation of keratin intermediate filaments. Curr. Opin. Cell Biol. 14:2002;110-122
9. Steinert P.M., Roop D.R. Molecular and cellular biology of intermediate filaments. Ann. Rev. Biochem. 57:1988;593-625
10. Lane E.B., Alexander C.M. Use of keratin antibodies in tumor diagnosis. Cancer Biol. 1:1990;2707-2714
11. Chu P.G., Weiss L.M. Keratin expression in human tissues and neoplasms. Histopathology. 40:2002;403-439
12. Ku N.O., Omary M.B. Identification of mutational analysis of the glycosylation sites of human cytokeratin 18. J. Biol. Chem. 270:1995;11820-11827
13. Ku N.O., Omary M.B. Identification of major physiologic phosphorylation site of human keratin 18: potential kinases and a role in filament reorganization. J. Cell Biol. 127:1994;161-171
14. Rydlander L., Ziegler E., Bergman T., et al. Molecular characterization of a tissue-polypeptide-specific-antigen epitope and its relationship to human cytokeratin 18. Eur. J. Biochem. 241:1996;309-314
15. Petak I., Houghton J.A. Shared pathways: death receptors and cytotoxic drugs in cancer therapy. Pathol. Oncol. Res. 7:2001;95-106
16. Fadeel B., Orrenius S., Zhivotovsky B. The most unkindest cut of all: on the multiple roles of mammalian caspases. Leukemia. 14:2000;1514-1525
17. Ku N.O., Omary M.B. Effect of mutation and phosphorylation of type I keratins on their caspase-mediated degradation. J. Biol. Chem. 276:2001;26792-26798
18. Leers M.P., Kölgen W., Björklund V., et al. Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J. Pathol. 187:1999;567-572
19. Caulin C., Salvesen G.S., Oshima R.G. Caspase cleavage of keratin 18 and reorganization of intermediate filaments during epithelial cell apoptosis. J. Biol. Chem. 138:1997;1379-1394
20. Sheard M.A., Vojtesek B., Simickova M., Valik D. Release of cytokeratin-18 and-19 fragments (TPS and CYFRA 21-1) into the extracellular space during apoptosis. J. Cell. Biochem. 85:2002;670-677
21. Stigbrand T., Andres C., Bellanger L., et al. Epitope specificity of 30 monoclonal antibodies against cytokeratin antigens: the ISOBM TD5-1 workshop. Tumor Biol. 19:1998;132-152
22. Nap M., van Wel Th., Andres C., et al. Immunohistochemical profiles of 30 monoclonal antibodies against cytokeratins 8, 18 and 19. Tumor Biol. 22:2001;4-10
23. Gion M., Boracchi P., Dittadi R., et al. Quantitative measurement of soluble cytokeratin fragments in tissue cytosol of 599 node negative breast cancer patients: a prognostic marker possibly associated with apoptosis. Breast Cancer Res. Treat. 59:2000;211-221
24. Lindman H., Jansson T., Arnberg H., Bergh J., Einarsson R. Serum markers TPS, TPA and CA 15-3 as monitors of chemotherapy in patients with metastatic breast cancer. J. Tumor Marker Oncol. 15:2000;177-186
25. Plebani M., Basso D., Navaglia F., De Paoli M., Tommasini A., Cipriani A. Clinical evaluation of seven tumor markers in lung cancer diagnosis: can any combination improve the results? Br. J. Cancer. 72:1995;170-173
26. Bennink R., Van Poppel H., Billen J., et al. Serum tissue polypeptide antigen (TPA): monoclonal or polyclonal radioimmunometric assay for the follow-up of bladder cancer. Anticancer Res. 19:1999;2609-2614
27. Nicolini A., Caciagli M., Zampieri F., et al. Usefulness of CEA, TPA, GICA, CA 72.4, and CA 195 in the diagnosis of primary colateral cancer and its relapse. Cancer Detect. Prev. 19:1995;183-195
28. Rosati G., Riccardi F., Tucci A. Use of tumor markers in the management of head and neck cancer. Int. J. Biol. Markers. 15:2000;179-183
29. Mellerick D.M., Osborn M., Weber K. On the nature of serological tissue polypeptide antigen (TPA); monoclonal keratin 8, 18 and 19 antibodies react differently with TPA prepared from human cultured carcinoma cells and TPA in human serum. Oncogene. 5:1990;1007-1017
30. Bodenmüller H., Ofenloch-Hähnle B., Lane E.B., Dessauer A., Bottger V., Donie F. Lung cancer-associated keratin 19-fragment: development and biochemical characterization of the new serum assay Enzymun Test CYFRA 21-1. Int. J. Biol. Markers. 9:1994;75-81
31. Nisman B., Lafair J., Heching N., Lyass O., Baras M., Barak V. Evaluation of tissue polypeptide specific antigen, CYFRA 21-1 and carcinoembryonic antigen in non small cell lung carcinoma: does the combined use of cytokeratin markers give an additional information? Cancer. 10:1998;1850-1859
32. Yen T.C., Lin W.Y., Kao C.H., Cheng K.Y., Wang S.J. A study of the new tumor marker, CYFRA 21-1, in squamous cell carcinoma of the head and neck, and comparison with squamous cell carcinoma antigen. Clin. Otolaryngol. 23:1998;82-86
33. Bonfrer J.M.G., Goenveld E.M., Korse C.M., Van Dalen A., Oomen L.C.J.M., Ivanyi D. Monoclonal antibody M3 used in tissue polypeptide-specific antigen assay for the quantification of tissue polypeptide antigen recognizes keratin 18. Tumor Biol. 15:1994;210-222
34. Einarsson R., Barak V. TPS: a cytokeratin serum tumor marker for effective therapy control of cancer patients with focus on breast cancer. J. Clin. Ligand Assay. 22:1999;348-351
35. van Dalen A., Heering K.J., Barak V., et al. Treatment response in metastatic breast cancer: a multicenter study comparing UICC criteria and tumor marker changes. Breast. 5:1996;82-88
36. van Dalen A., Barak V., Cremaschi A., et al. The prognostic significance of increasing marker levels in metastatic breast cancer patients with clinically complete remission, partial remission or stable disease. A multicenter study. Int. J. Biol. Markers. 13:1998;10-15
37. Kramer G., Steiner G., Madersbacher S., Stulnig T., Lang T., Marberger M. Serial tissue polypeptide specific antigen in the follow-up of hormone treated carcinoma of the prostate. J. Urol. 158:1997;1446-1451
38. Polito M., Minardi D., Recchioni A., Giannulis L., De Sio G., Muzzonigro G. Serum markers for monitoring of prostatic carcinoma. Prostate. 33:1997;208-216
39. Kil P.J., Goldschmidt H.M., Wieggers B.J., et al. Tissue polypeptide specific antigen (TPS) determination before and during intermittent maximal androgen blockade in patients with prostatic carcinoma. Eur. Urol. 43:2003;31-38
40. van Dalen A., Favier J., Burges A., et al. Prognostic significance of CA 125 and TPS levels after 3 chemotherapy courses in ovarian cancer patients. Gynecol. Oncol. 79:2000;444-450
41. Glimelius B., Hoffman K., Einarsson R., Påhlman L., Graf W. Monitoring palliative chemotherapy in advanced gastrointestinal cancer using serial tissue polypeptide specific antigen (TPS) measurements. Acta Oncol. 35:1996;141-148
42. Berglund Å., Molin D., Larsson A., Einarsson R., Glimelius B. Tumor markers as early predictors of response to chemotherapy in advanced colorectal carcinoma. Ann. Oncol. 13:2002;1430-1437
43. Bjorklund B., Einarsson R. TPS (tissue polypeptide specific antigen) in oncologic practice: a review with reference to 3000 cases of breast cancer. Tumordiagn Ther. 17:1996;67-73
44. Giai M., Roagna R., Ponzone R., et al. TPS and CA15-3 serum values as a guide for treating and monitoring breast cancer patients. Anticancer Res. 15:1995;2711-2716
45. Barak V., Nisman B., Roisman I., Hubert A., Burde B., Peretz T. TPS in evaluation of response to Taxol and interferon therapy in breast cancer patients. J. Tumor Marker Oncol. 9:1994;89
46. Barak V., Nisman B., Roisman I., et al. TPS in assessing response to therapy and prognosis of breast cancer patients treated with interferons. J. Tumor Marker Oncol. 12:1997;17-26
47. Barak V., Gimmon Z., Libson Y., et al. Breast cancer detection by mammography, CA 15-3 and TPS. J. Tumor Marker Oncol. 10:1995;51-52
48. Barak V., Nisman B., Roisman I., Hubert A., Peretz T. Clinical utility of TPS in breast cancer. Tumor Biol. 19:1998;59
49. Barak V., Nisman B., Hubert A., Peretz T. TPS-prognosticator in breast cancer. Anticancer Res. 18:1998;4982
50. Findeisen R., Albrecht S., Richter B., Deutschmann K., Distler W. Comparison of tissue polypeptide antigen (TPA) with cancer antigen 15-3 (CA 15-3) and carcinoembryonic antigen (CEA) in follow-up of breast cancer. Clin. Chem. Lab. Med. 36:1998;841-846
51. Soletormos G., Hyltoft Petersen P., Dombernowsky P. Assessment of CA15-3, CEA and TPA concentrations during monitoring of breast cancer. Clin. Chem. Club Med. 38:2000;453-463
52. Nicolini A., Carpi A., Ferrari P., Anselmi L. Clinical use of tumor markers in the postoperative management of breast cancer patients: new concepts. Int. J. Biol. Markers. 12:1997;181-186
53. Nekulova M., Simickova M., Pecen L., et al. Early diagnosis of breast cancer dissemination by tumor markers follow-up and method of prediction. Neoplasma. 41:1994;113-118
54. Nicolini A., Colombini C., Luciani L., Carpi A., Giuliani L. Evaluation of serum CA15-3 determination with CEA and TPA in the post-operative follow-up of breast cancer patients. Br. J. Cancer. 64:1991;154-158
55. Barak V., Anteby S.O., Edelman D., Halperin T., Roisman I., Perez T. CA 125 - The ovarian cancer tumor marker. Israeli Cancer J. Bamah. l7:1993;10-14
56. van Dalen A., Favier J., Baumgartner L., et al. Prognostic significance of CA 125 and TPS levels after chemotherapy in ovarian cancer patients. Anticancer Res. 19:1999;2523-2526
57. Chechlinska M., Kaminska J., Kowalska M., Radziszewski J., Steffen J. The origin of cytokines, soluble cytokine receptors and CA125 in ascitic fluids and sera of ovarian cancer patients. Tumor Biol. 24:2003;76
58. Sedlaczek P., Frydecka I., Gabrys M., van Dalen A., Einarsson R., Harlozinska A. Comparative analysis of CA125, Tissue Polypeptide Specific antigen, and soluble Interleukin-2 receptor alfa levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma. Cancer. 95:2002;1886-1893
59. Hording U., Toftager-Larsen K., Dreisler A., et al. CA 125, placental alkaline phosphatase, and tissue polypeptide antigen in the monitoring of ovarian carcinoma. A comparative study of three different tumor markers. Gynecol. Obstet. Invest. 30:1990;178-183
60. Tholander B., Taube A., Lindgren A., Sjoberg O., Stendahl U., Tamsen L. Pretreatment serum levels of CA-125, carcinoembryonic antigen, tissue polypeptide antigen, and placental alkaline phosphatase in patients with ovarian carcinoma: influence of histological type, grade of differentiation, and clinical stage of disease. Gynecol. Oncol. 39:1990;26-33
61. Toftager-Larsen K., Hording U., Dreisler A., et al. CA-125, placental alkaline phosphatase and tissue polypeptide antigen as preoperative serum markers in ovarian carcinoma. Gynecol. Obstet. Invest. 33:1992;177-182
62. Panza N., Pacilio G., Campanella L., et al. Cancer antigen 125, tissue polypeptide antigen, carcinoembryonic antigen, and beta-chain human chorionic gonadotropin as serum markers of epithelial ovarian carcinoma. Cancer. 61:1988;76-83
63. Hasholzner U., Baumgartner L., Stieber P., Meier W., Hofmann K., Fateh-Moghadam A. Significance of the tumour markers CA 125 II, CA 72-4, CASA and CYFRA 21-1 in ovarian carcinoma. Anticancer Res. 14:1994;2743-2746
64. Tempfer C., Hefler L., Heinzl H., et al. CYFRA 21-1 serum levels in women with adnexal masses and inflammatory diseases. Br. J. Cancer. 78:1998;1108-1112
65. Duffy M.J. CA 19-9 as a marker for gastrointestinal cancers: a review. Ann. Clin. Biochem. 35:1998;364-370
66. Slesak B., Harlozinska-Szmyrka A., Knast W., Sedlaczek P., van Dalen A., Einarsson R. Tissue polypeptide specific antigen (TPS), a marker for differentiation between pancreatic carcinoma and chronic pancreatitis. Cancer. 89:2000;83-88
67. Leo M.E., Bilhartz D.L., Bergstrahl E.J., Oesterling J.E. Prostate specific antigen in hormonally treated stage D2 prostate cancer: is it always an accurate indicator of disease status? J. Urol. 145:1991;802-806
68. Banal A., Hacene K., Berthelot-Ruff E., Mahe E., Fontana X., Pichon M.F. Comparison of Cyfra 21-1 and SCC assays in head and neck tumors. Tumor Biol. 22:2001;27-35
69. Molina R., Torres M.D., Moragas M., et al. Prognostic value of TPS in patients with head and neck malignancies: comparison with SCC. Anticancer Res. 15:1995;479-484
70. Sanislo L., Kausitz J. Predictive value of cytokeratin 18 fragments in patients with locally advanced head and neck tumors. Tumor Biol. 24:2003;80
71. Nagler R.M., Barak M., Peled M., Ben-Aryeh H., Filatov M., Laufer D. Early diagnosis and treatment monitoring roles of tumour markers Cyfra 21-1 and TPS in oral squamous cell carcinoma. Cancer. 85:1999;1018-1025
72. Pujol J.L., Grenier J., Daures J.P., Daver A., Pujol H., Michel F.B. Serum fragments of cytokeratin subunit 19 measured by Cyfra 21-1 immunoradiometric assay as a marker of lung cancer. Cancer Res. 53:1993;1-6
73. Buccheri G.F., Ferrigno D. Usefulness of tissue polypeptide antigen in staging, monitoring and prognosis of lung cancer. Chest. 93:1989;565-570
74. Kulpa J., Wojcik E., Reinfuss M., Kolodziejski L. Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients. Clin. Chem. 48:2002;1931-1937
75. Nisman B., Lafair J., Heshing N., Lyass O., Peretz T., Barak V. Prognostic value of CEA, Cyfra 21-1 and TPS in different subtypes of lung cancer. Anticancer Res. 18:1998;4982
76. Devine P.L., Yarker J., Fong K., et al. Serum markers CASA, CEA, CYFRA 21-1, MSA, NSE, TPA and TPS in lung cancer. Int. J. Oncol. 4:1994;1129-1135
77. Pujol J.L., Grenier J., Parrat E., et al. Cytokeratins as serum markers in lung cancer: a comparison of Cyfra 21-1 and TPS. Am. J. Respir. Crit. Care Med. 154:1996;725-733
78. Ebert W., Muley Th. Cyfra 21-1, TPS and NSE in the follow-up of non-small (NSCLC) and small cell lung cancer (SCLC). Anticancer Res. 18:1998;4983
79. Stieber P., Dienemann H., Hasholzner U., et al. Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and tissue polypeptide specific antigen (TPS) as tumour markers in lung cancer. Eur. J. Clin. Chem. Clin. Biochem. 31:1993;689-694
80. Stieber P., Zimmermann A., Reinmiedl J., Muller C., Hoffmann H., Dienemann H. CYFRA 21-1 in the early diagnosis of recurrent disease in non small cell lung carcinomas (NSCLC). Anticancer Res. 19:1999;2665-2668
81. Molina R., Filella X., Auge M., et al. Tumor markers (CEA, CA125, CYFRA21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological prognosis factors. Tumor Biol. 24:2003;209-218
82. Nisman B., Barak V., Heching N., Kramer M., Reinus C., Lafair J. Cytokeratin markers in malignant pleural mesothelioma. Cancer Detect. Prev. 22:1998;416-422
83. Correale M., Arnberg H., Blockx P., et al. Clinical profile of a new monoclonal antibody-based immunoassay for tissue polypeptide antigen. Int. J. Biol. Markers. 9:1994;231-238
84. Mizushima Y., Hirata H., Izumi S., et al. Clinical significance of the number of positive tumor markers in assisting the diagnosis of lung cancer with multiple tumor marker assay. Oncology. 47:1990;43-48
85. Spinazzi A., Soresi E., Boffi R., et al. Evaluation of neuron-specific enolase, tissue polypeptide antigen, and carcinoembryonic antigen as markers for staging and monitoring response to therapy of lung cancer. Cancer Detect. Prev. 18:1994;209-220
86. Buccheri G., Ferrigno D. Prognostic value of the tissue polypeptide antigen in lung cancer. Chest. 101:1992;1287-1292
87. Rapellino M., Piantino P., Pecchio F., et al. Disappearance curves of tumor markers after radical surgery. Int. J. Biol. Markers. 9:1994;33-37
88. Carpelan-Holmstrom M., Haglund C., Lundin J., Alfthan H., Stenman U.H., Roberts P.J. Independent prognostic value of preoperative serum markers CA242, tissue polypeptide antigen and human chronic gonadotrophin beta, but not of carcinoembryonic antigen of tissue polypeptide antigen in colorectal cancer. Br. J. Cancer. 74:1996;925-929
89. von Kleist S., Hesse Y., Kananeeh H. Comparative evaluation of four tumor markers, CA 242, CA 19/9, TPA and CEA in carcinomas of the colon. Anticancer Res. 16:1996;2325-2331
90. Maulard C., Toubert M.E., Chretien Y., Delanian S., Dufour B., Housset M. Serum tissue polypeptide antigen (S-TPA) in bladder cancer as a tumor marker. A prospective study. Cancer. 73:1994;394-398
91. Maulard-Durdux C., Toubert M.E., Hennequin C., Housset M. Serum tissue polypeptide antigen in bladder cancer as a tumor marker: a prospective study. J. Clin. Oncol. 15:1997;3446-3450
92. Filella X., Menendez V., Molina R., Alcover J., Carretero P., Ballesta A.M. TPA prognostic value in superficial bladder cancer. Anticancer Res. 16:1996;2173-2175
93. Schmidt A., Bub P., Ruther U., Eisenberger F. Tissue polypeptide antigen for monitoring of advanced bladder cancer after MVEC chemotherapy. Eur. Urol. 21:1992;10-12
94. van Poppel H., Billen J., Goethuys H., et al. Serum tissue polypeptide antigen (TPA) as tumor marker for bladder cancer. Anticancer Res. 16:1996;205-207
95. Nisman B., Barak V., Shapiro A., Golijanin D., Peretz T., Pode D. Evaluation of urine CYFRA 21-1 for the detection of primary and recurrent bladder cancer. Cancer. 94:2002;2914-2922
96. Senga Y., Kimura G., Hattori T., Yoshida K. Clinical evaluation of soluble cytokeratin 19 fragments (CYFRA 21-1) in serum and urine of patients with bladder cancer. Urology. 48:1996;703-710
97. Sanchez-Carbayo M., Herrero E., Megias J., Mira A., Soria F. Comparative sensitivity of urinary CYFRA 21-1, urinary bladder cancer antigen, and NMP22 to detect bladder cancer. J. Urol. 162:1999;1951-1956
98. Yao W., Chang C.J., Chan S.H., et al. Significance of urinary tissue polypeptide specific antigen (TPS) determination in patients with urothelial carcinoma. Anticancer Res. 15:1995;2819-2824
99. Sánchez-Carbayo M., Herrero E., Megias J., et al. Initial evaluation of the diagnostic performance of the new urinary bladder cancer antigen test as a tumor marker for transitional cell carcinoma of the bladder. J. Urol. 161:1999;1110-1115
100. Sumi S., Arai K., Kithara S., Yoshida K. Preliminary report of the clinical performance of a new urinary bladder cancer antigen test: comparison to voided urine cytology in the detection of transitional cell carcinoma of the bladder. Clin. Chim. Acta. 296:2000;111-120
101. Giannopoulos A., Manousakas T., Gounari A., Constantinides C., Choremi-Papadopoulou H., Dimopoulos C. Comparative evaluation of the diagnostic performance of the BTA stat test, NMP22 and urinary bladder cancer antigen for primary and recurrent bladder tumors. J. Urol. 166:2001;470-475
102. Sánchez-Carbayo M., Urrutia M., Silva J.M., Romani R., González de Buitrago J.M., Navajo J.A. Comparative predictive values of urinary cytology, urinary bladder cancer antigen, CYFRA 21-1 and NMP22 for evaluating symptomatic patients at risk for bladder cancer. J. Urol. 165:2001;1462-1467
103. Sánchez-Carbayo M., Urrutia M., González de Buitrago J.M., Navajo J.A. Utility of serial urinary tumor markers to individualize intervals between cystoscopies in the monitoring of patients with bladder carcinoma. Cancer. 92:2001;2820-2828